Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

524
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

720
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
720
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comprehensive mapping of identical sequences across human proteins emphasizes the widespread issue of shared epitopes in self-antigens.

NAR genomics and bioinformatics·2026
Same author

Rethinking EPO: A Paradigm Shift in Oncology?

Cancers·2025
Same author

Dihydropyrimidine Dehydrogenase-Guided Dosing of 5-Fluorouracil: Prioritizing Precision Over Dose Reduction.

JCO precision oncology·2025
Same author

PROTACs and Glues: Striking Perspectives for Engineering Cancer Therapy À La Carte.

Pharmaceuticals (Basel, Switzerland)·2025
Same author

De-Escalating Anticancer Treatment: Watch Your Step.

Cancers·2025
Same author

Long-Term Adverse Events Following Early Breast Cancer Treatment with a Focus on the <i>BRCA</i>-Mutated Population.

Cancers·2025
Same journal

RETRACTED: Meligy et al. Therapeutic Potential of Mesenchymal Stem Cells Versus Omega n - 3 Polyunsaturated Fatty Acids on Gentamicin-Induced Cardiac Degeneration. <i>Pharmaceutics</i> 2022, <i>14</i>, 1322.

Pharmaceutics·2026
Same journal

Correction: Mohite et al. Bioactive Compound-Fortified Nanomedicine in the Modulation of Reactive Oxygen Species and Enhancement of the Wound Healing Process: A Review. <i>Pharmaceutics</i> 2025, <i>17</i>, 855.

Pharmaceutics·2026
Same journal

Metal Nanoparticle-Reinforced Hydrogels Applied in the Inhibition of Clinical Pathogens: Structural Features, Mechanisms, and Biomedical Prospects.

Pharmaceutics·2026
Same journal

Development and Evaluation of a Physiologically Based Pharmacokinetic Model for Cipepofol Across Diverse Clinical Populations.

Pharmaceutics·2026
Same journal

Artificial Intelligence in Nanopharmaceutical Development: From Predictive Design to Clinical Translation.

Pharmaceutics·2026
Same journal

Textilinin-1, a Snake Venom-Derived Kunitz-Type Protease Inhibitor, Accelerates Wound Healing Through Anti-Inflammatory, Antibacterial, and Pro-Regenerative Activities.

Pharmaceutics·2026
See all related articles

Related Experiment Video

Updated: Jul 2, 2025

Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments
07:46

Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments

Published on: April 30, 2021

4.7K

Artificial Intelligence and Anticancer Drug Development-Keep a Cool Head.

Caroline Bailleux1, Jocelyn Gal2, Emmanuel Chamorey2

  • 1Centre Antoine Lacassagne, Oncology Departement Unit, University Côte d'Azur, 06000 Nice, France.

Pharmaceutics
|February 24, 2024
PubMed
Summary
This summary is machine-generated.

Artificial intelligence (AI) is transforming oncology drug development by predicting drug toxicity and efficacy. AI-powered in silico clinical trials promise to reduce trial times and costs, revolutionizing cancer research.

Keywords:
artificial intelligencenew drug discoveryoncologyserendipity

More Related Videos

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

3.6K
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.7K

Related Experiment Videos

Last Updated: Jul 2, 2025

Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments
07:46

Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments

Published on: April 30, 2021

4.7K
A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

3.6K
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.7K

Area of Science:

  • Oncology
  • Computational Chemistry
  • Bioinformatics

Background:

  • Artificial intelligence (AI) is increasingly integrated into healthcare, especially in oncology.
  • AI enables prediction of drug toxicity and efficacy using computer-designed molecular structures.

Purpose of the Study:

  • To highlight the potential of AI in oncology drug development.
  • To emphasize the significance of AI-based in silico clinical trials.

Main Methods:

  • Utilizing AI for predicting molecular structure-based drug toxicity and efficacy.
  • Exploring the application of AI in silico clinical trials for oncology.

Main Results:

  • AI offers novel approaches to predict drug properties, potentially streamlining development.
  • AI-based in silico trials are emerging, with expectations of reduced duration and cost.

Conclusions:

  • AI presents a new paradigm for oncology drug development.
  • Health authorities should consider AI as a foundational element for future clinical research in oncology.